• Home
  • Contacts
  • Program Description
  • FP7 Grant
  • Consortium
  • Orphan drug
  • ARDS
  • News
 

News

8.5. 2018 Faron announces top line data from the Phase III INTEREST trial with Traumakine in the treatment of ARDS

11.12. 2017 Recruitment completed in Traumakine INTEREST Trial

29.12. 2015 First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome

4.2. 2014 The Lancet Respiratory Medicine article now published

30.12. 2013 The TRAUMAKINE consortium receives scientific advise from the EMA on the FP-1201-lyo clinical development

29.11. 2012 European commission has granted €6 million for Traumakine orphan program.

Coordinator: Faron Pharmaceuticals, Ltd. Joukahaisenkatu 6, Intelligate, FIN-20520 TURKU Finland, Phone: +358 2 469 5151, Email: info@traumakine.eu

The content of these pages are for information purposes only.